CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nurexone Biologic Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nurexone Biologic Inc
9 Mezada Street, Bsr 3 Tower, 30 Floor
Phone: (416) 410-5297p:416 410-5297 BNEI BRAK, 5120109  Israel Ticker: WAL.PWAL.P
Business Summary
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer James A.Richardson 12/8/2016 6/27/2011
Chief Financial Officer, Corporate Secretary, Director John G.Arnold 75 12/8/2016 3/25/2015
Director John-PeterBradford 12/9/2019 12/9/2019
Independent Director Peter R.Andrews 46 1/1/2013 12/12/2011

Business Names
Business Name
5E0
ENER
J90
4 additional Business Names available in full report.

General Information
Number of Employees: 8 (As of 12/31/2022)
Outstanding Shares: 70,893,598 (As of 11/25/2024)
Stock Exchange: CVE
Fax Number: (416) 410-5297


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024